Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

RTTR has been the topic of several other research reports. Maxim Group restated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Chardan Capital decreased their target price on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Ritter Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $4.83.

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) opened at 0.5022 on Friday. The firm’s market cap is $7.41 million. Ritter Pharmaceuticals has a 12-month low of $0.48 and a 12-month high of $3.75. The company has a 50-day moving average of $0.55 and a 200 day moving average of $0.55.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). Equities analysts predict that Ritter Pharmaceuticals will post ($0.42) EPS for the current year.

WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/23/ritter-pharmaceuticals-inc-rttr-lowered-to-hold-at-zacks-investment-research.html.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. boosted its position in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 105,409 shares of the biotechnology company’s stock after acquiring an additional 76,046 shares during the period. KCG Holdings Inc. owned 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent quarter. 7.55% of the stock is owned by hedge funds and other institutional investors.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.